You are here:
The medical technology company Dermagnostix GmbH is a joint spin-off of Helmholtz Munich, the Technical University (TU) Munich and Hahn-Schickard. Its goal: to redefine molecular diagnostics in dermatology. Dermagnostix has now qualified as one of 30…
Researchers at Helmholtz Munich are working toward a world without diabetes. They are not doing so alone, but with a network of organizations, hospitals, and pharmaceutical companies. Their goal is to use experts’ knowledge to create something new:…
A team of researchers from Helmholtz Munich, the German Center for Diabetes Research (DZD) and Novo Nordisk have developed a new hormone combination for the future treatment of type 2 diabetes. The scientists have combined the blood sugar-reducing…
The Epstein-Barr virus (EBV) has been known for some time to play a part in a range of diseases. A current US study has now shown a close link between EBV and multiple sclerosis. Scientists at Helmholtz Munich and DZIF are already working on…
Researchers have designed antibodies as novel therapeutic candidates for the treatment of chronic hepatitis B and hepatocellular carcinoma. Their study in human cell cultures and in living mice showed the elimination of antigen-positive cells and…
A newly engineered organoid on chip platform mimics robustly key features of human pancreas development. This is a stepping stone towards reliable diagnostic solutions for early-stage pancreatic cancer. The study was carried out by an…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
